Close Menu

NEW YORK (GenomeWeb) – Pharmaceutical firm Arcus Biosciences and precision oncology firm Strata Oncology have entered into a clinical development collaboration in which they will use Strata's biomarker technology to identify responders to Arcus' clinical-stage anti-PD-1 antibody AB122 among a variety of tumor types that don't normally show response to such drugs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.